|
|
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.US |
First Approval Date15 Mar 1949 |
A Phase 1 Study of SP-02L (Darinaparsin for Injection) in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL) in Korea
The purpose of this study is to evaluate the safety and tolerability of SP-02L monotherapy in Korean patients with relapsed or refractory Peripheral T-cell Lymphoma (PTCL).
100 Clinical Results associated with Synex Consulting Korea Ltd.
0 Patents (Medical) associated with Synex Consulting Korea Ltd.
100 Deals associated with Synex Consulting Korea Ltd.
100 Translational Medicine associated with Synex Consulting Korea Ltd.